%0 Journal Article
%A Janssens, Geert O
%A Gandola, Lorenza
%A Bolle, Stephanie
%A Mandeville, Henry
%A Ramos-Albiac, Monica
%A van Beek, Karen
%A Benghiat, Helen
%A Hoeben, Bianca
%A Morales La Madrid, Andres
%A Kortmann, Rolf-Dieter
%A Hargrave, Darren
%A Menten, Johan
%A Pecori, Emilia
%A Biassoni, Veronica
%A von Bueren, Andre O
%A van Vuurden, Dannis G
%A Massimino, Maura
%A Sturm, Dominik
%A Peters, Max
%A Kramm, Christof M
%T Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group.
%J European journal of cancer
%V 73
%@ 0959-8049
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2017-00925
%P 38 - 47
%D 2017
%X Overall survival (OS) of patients with diffuse intrinsic pontine glioma (DIPG) is poor. The purpose of this study is to analyse benefit and toxicity of re-irradiation at first progression.At first progression, 31 children with DIPG, aged 2-16 years, underwent re-irradiation (dose 19.8-30.0 Gy) alone (n = 16) or combined with systemic therapy (n = 15). At initial presentation, all patients had typical symptoms and characteristic MRI features of DIPG, or biopsy-proven high-grade glioma. An interval of ≥3 months after upfront radiotherapy was required before re-irradiation. Thirty-nine patients fulfilling the same criteria receiving radiotherapy at diagnosis, followed by best supportive care (n = 20) or systemic therapy (n = 19) at progression but no re-irradiation, were eligible for a matched-cohort analysis.Median OS for patients undergoing re-irradiation was 13.7 months. For a similar median progression-free survival after upfront radiotherapy (8.2 versus 7.7 months; P = .58), a significant benefit in median OS (13.7 versus 10.3 months; P = .04) was observed in favour of patients undergoing re-irradiation. Survival benefit of re-irradiation increased with a longer interval between end-of-radiotherapy and first progression (3-6 months: 4.0 versus 2.7; P < .01; 6-12 months: 6.4 versus 3.3; P = .04). Clinical improvement with re-irradiation was observed in 24/31 (77
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:28161497
%R 10.1016/j.ejca.2016.12.007
%U https://inrepo02.dkfz.de/record/120496